NasdaqGS:BEAMBiotechs
Beam Therapeutics (BEAM) Quarterly Profit Surprises Loss Narrative With US$244.3 Million Net Income
Beam Therapeutics (BEAM) just posted its FY 2025 numbers with Q4 revenue of US$114.1 million and basic EPS of US$2.37, alongside trailing 12 month revenue of US$139.7 million and a basic EPS loss of US$0.81. Over the past six quarters, the company has seen quarterly revenue range from US$7.5 million to US$114.1 million, while basic EPS has swung from a loss of US$1.24 per share to a gain of US$2.37 per share, reflecting a wide earnings range around its R&D heavy model. For investors, the...